WCLC 2025 - Posters & ePosters-P1.17.69 A Real-World Study of Advanced ALK-Fusion NSCLC Patients Receiving First-Line ALK-TKI Therapy with Telehealth Care

P1.17.69 A Real-World Study of Advanced ALK-Fusion NSCLC Patients Receiving First-Line ALK-TKI Therapy with Telehealth Care

Back to course

Pdf Summary

This real-world study evaluated advanced ALK fusion-positive non-small cell lung cancer (NSCLC) patients receiving first-line ALK-tyrosine kinase inhibitor (ALK-TKI) therapy integrated with telehealth care via the WeDoc platform. A total of 174 treatment-naïve patients were enrolled from 15 hospitals in China between June 2021 and September 2024, receiving alectinib (n=102), brigatinib (n=40), or lorlatinib (n=32). The study compared progression-free survival (PFS), objective response rates (ORR), adverse events (AEs), and influencing factors including clinical characteristics and telehealth engagement.<br /><br />Results showed median PFS for alectinib was 31 months, while PFS for brigatinib and lorlatinib remained unreached because of limited follow-up time. ORR was similar across groups (alectinib 80.3%, brigatinib 86.7%, lorlatinib 84.2%), and no significant differences in PFS or AEs were observed among the three ALK-TKIs. In the alectinib subgroup, multivariate analysis identified brain metastasis and a high frequency of patient-physician communication via the telehealth platform as independent factors associated with prolonged PFS. Importantly, frequent communication did not adversely impact AEs or patient-reported outcomes.<br /><br />The study concluded that integrating the WeDoc telehealth system with ALK-TKI therapy may enhance real-world treatment outcomes by facilitating close doctor-patient interaction, potentially contributing to extended PFS without negatively affecting safety. These findings support the benefit of telehealth care as a complementary tool in managing advanced ALK fusion NSCLC. However, confirmation through prospective randomized trials is recommended to validate these observational results.

Asset Subtitle

Di Zheng

Meta Tag

Speaker Di Zheng

Topic Global Health, Health Services, and Health Economics

Keywords

ALK fusion-positive NSCLC

ALK-tyrosine kinase inhibitors

alectinib

brigatinib

lorlatinib

telehealth care

WeDoc platform

progression-free survival

objective response rate

brain metastasis